無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

レット症候群:パイプライン製品の分析

Rett Syndrome - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 359401
出版日 ページ情報 英文 122 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.11円で換算しております。
Back to Top
レット症候群:パイプライン製品の分析 Rett Syndrome - Pipeline Review, H2 2018
出版日: 2018年10月09日 ページ情報: 英文 122 Pages
概要

当レポートでは、レット症候群治療薬の開発状況について調査分析しており、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどの情報を提供しています。

イントロダクション

  • 調査範囲

レット症候群の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

レット症候群:企業で開発中の治療薬

レット症候群:大学/機関で研究中の治療薬

レット症候群:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

レット症候群:企業で開発中の製品

レット症候群:大学/機関で研究中の製品

レット症候群の治療薬開発に従事している企業

  • Anavex Life Sciences Corp.
  • ArmaGen Inc.
  • Edison Pharmaceuticals, Inc.
  • GW Pharmaceuticals Plc
  • 田辺三菱製薬
  • Neuren Pharmaceuticals Limited
  • Neurolixis Inc.
  • Newron Pharmaceuticals S.p.A.
  • OPKO Health, Inc.
  • Oryzon Genomics S.A.
  • PharmatrophiX, Inc.
  • Raptor Pharmaceutical Corp.
  • Sage Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.

レット症候群:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

レット症候群:最近のパイプライン動向

レット症候群:休止中のプロジェクト

レット症候群:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Rett Syndrome, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Rett Syndrome - Pipeline by AMO Pharma Ltd, H2 2018
  • Rett Syndrome - Pipeline by Amorsa Therapeutics Inc, H2 2018
  • Rett Syndrome - Pipeline by Anavex Life Sciences Corp, H2 2018
  • Rett Syndrome - Pipeline by ArmaGen Inc, H2 2018
  • Rett Syndrome - Pipeline by AveXis Inc, H2 2018
  • Rett Syndrome - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
  • Rett Syndrome - Pipeline by Eloxx Pharmaceuticals Inc, H2 2018
  • Rett Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2018
  • Rett Syndrome - Pipeline by Mitochon Pharmaceuticals Inc, H2 2018
  • Rett Syndrome - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
  • Rett Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H2 2018
  • Rett Syndrome - Pipeline by Neurolixis Inc, H2 2018
  • Rett Syndrome - Pipeline by Newron Pharmaceuticals SpA, H2 2018
  • Rett Syndrome - Pipeline by OPKO Health Inc, H2 2018
  • Rett Syndrome - Pipeline by Relmada Therapeutics Inc, H2 2018
  • Rett Syndrome - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018
  • Rett Syndrome - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Rett Syndrome, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC10859IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H2 2018, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Rett Syndrome - Overview
  • Rett Syndrome - Therapeutics Development
  • Rett Syndrome - Therapeutics Assessment
  • Rett Syndrome - Companies Involved in Therapeutics Development
  • Rett Syndrome - Drug Profiles
  • Rett Syndrome - Dormant Projects
  • Rett Syndrome - Product Development Milestones
  • Appendix
Back to Top